Document Type : Original Article


1 Department of Biology, Mashhad Branch, Islamic Azad University, Mashhad, Iran

2 Burn and Wound Healing Research Center, Shiraz University of Medical Sciences, 71345-1978,Shiraz, Iran

3 Department of Biology, Faculty of Science, Mashhad Branch, Islamic Azad University, Mashhad, Iran


Objectives: Diabetes mellitus type 1 (T1DM), which is also an autoimmune disorder, can coexist alongside other types of autoimmune diseases. This study aimed to investigate the possibility of a subclinical association between diabetes disease and autoimmune thyroid dysfunction. The clinical condition of the patient and their approach to managing their diabetes were specifically considered when deciding whether or not the patient had autoantibodies.
Methods: This study included sixty individuals who were diagnosed with diabetes type 1. (thirty males and thirty women, with a mean age of 21.04 years) and 30 healthy controls (12 males and 18 females).
Results: Diabetics had considerably greater serum IL-10, IL-6, and TNF-α levels than healthy controls. Stepwise regression indicated significant positive correlations between IL-10, IL-6, and TNF-α with these antibodies and strong inversed relationships between IL-6 and Anti-TPO, Anti-TG, antibodies.
. No matter if the antibodies were present or how severe they were, this held true. The study's findings lend credence to the idea that people with type 1 diabetes should have their thyroid antibodies and function checked.
Conclusions: Thyroid antibodies were most common among type 1 diabetics aged 21–35, according to our study (Anti-TPO and Anti-TG). IL-10, IL-6, and TNF-α levels in diabetic patients and controls were significantly different (P<0.01). IL-10, TNF-α, HbA1C, and body mass index positively correlated with thyroid antibodies, except for IL-6. Thyroid antibodies and functional abnormalities should be tested often in type 1 diabetics due to the high occurrence of thyroid autoimmune illnesses.


Main Subjects

1.Eisenbarth GS. Type I diabetes mellitus. A chronic autoimmune disease. The New England journal of medicine. 1986;314(21):1360-8.
2.Bottazzo GF, Florin-Christensen A, Doniach D. Islet-cell antibodies in diabetes mellitus with autoimmune polyendocrine deficiencies. Lancet (London, England). 1974;2(7892):1279-83.
3.Gierach M, Gierach J, Junik R. Insulin resistance and thyroid disorders. Endokrynologia Polska. 2014;65(1):70-6.
4.Voulgari PV, Venetsanopoulou AI, Kalpourtzi N, Gavana M, Vantarakis A, Hadjichristodoulou C, et al. Thyroid dysfunction in Greece: Results from the national health examination survey EMENO. PloS one. 2022;17(3):e0264388.
5.Salloum M, Poole R. The challenges of managing type 1 diabetes with other autoimmune diseases. Practical Diabetes. 2022;39(5):32-5a.
6.Chan JCN, Lim L-L, Wareham NJ, Shaw JE, Orchard TJ, Zhang P, et al. The <em>Lancet</em> Commission on diabetes: using data to transform diabetes care and patient lives. The Lancet. 2020;396(10267):2019-82.
7.National Institute of Diabetes and Digestive Diseases. National Diabetes Statistics fact sheet: general information and national estimates on diabetes in the United States. 2005.
8.Bogusławska J, Godlewska M, Gajda E, Piekiełko-Witkowska A. Cellular and molecular basis of thyroid autoimmunity. European thyroid journal. 2022;11(1).
9.Glassman CR, Su L, Majri-Morrison SS, Winkelmann H, Mo F, Li P, et al. Calibration of cell-intrinsic interleukin-2 response thresholds guides design of a regulatory T cell biased agonist. eLife. 2021;10:e65777.
10.Antonelli A, Ferrari SM, Corrado A, Di Domenicantonio A, Fallahi P. Autoimmune thyroid disorders. Autoimmunity reviews. 2015;14(2):174-80.
11.Fernández-Castañer M, Molina A, López-Jiménez L, Gómez JM, Soler J. Clinical presentation and early course of type 1 diabetes in patients with and without thyroid autoimmunity. Diabetes care. 1999;22(3):377-81.
12.Kim YS, Han K, Lee JH, Kim NI, Roh JY, Seo SJ, et al. Increased Risk of Chronic Spontaneous Urticaria in Patients With Autoimmune Thyroid Diseases: A Nationwide, Population-based Study. Allergy, asthma & immunology research. 2017;9(4):373-7.
13.Pedullá M, Fierro V, Papacciuolo V, Alfano R, Ruocco E. Atopy as a risk factor for thyroid autoimmunity in children affected with atopic dermatitis. Journal of the European Academy of Dermatology and Venereology : JEADV. 2014;28(8):1057-60.
14.Kylökäs A, Kaukinen K, Huhtala H, Collin P, Mäki M, Kurppa K. Type 1 and type 2 diabetes in celiac disease: prevalence and effect on clinical and histological presentation. BMC gastroenterology. 2016;16(1):76.
15.Prazny M, Skrha J, Limanova Z, Vanickova Z, Hilgertova J, Prazna J, et al. Screening for associated autoimmunity in type 1 diabetes mellitus with respect to diabetes control. Physiological research. 2005;54(1):41-8.
16.Incidence and trends of childhood Type 1 diabetes worldwide 1990-1999. Diabetic medicine : a journal of the British Diabetic Association. 2006;23(8):857-66.
17.Steck AK, Johnson K, Barriga KJ, Miao D, Yu L, Hutton JC, et al. Age of islet autoantibody appearance and mean levels of insulin, but not GAD or IA-2 autoantibodies, predict age of diagnosis of type 1 diabetes: diabetes autoimmunity study in the young. Diabetes care. 2011;34(6):1397-9.
18.Jongejan RMS, van Velsen EFS, Meima ME, Klein T, van den Berg SAA, Massolt ET, et al. Change in Thyroid Hormone Metabolite Concentrations Across Different Thyroid States. Thyroid : official journal of the American Thyroid Association. 2022;32(2):119-27.
19.Kadiyala R, Peter R, Okosieme OE. Thyroid dysfunction in patients with diabetes: clinical implications and screening strategies. International journal of clinical practice. 2010;64(8):1130-9.
20.Levin L, Tomer Y. The etiology of autoimmune diabetes and thyroiditis: evidence for common genetic susceptibility. Autoimmunity Reviews. 2003;2(6):377-86.
21.Liu Z, Zhang L, Qian C, Zhou Y, Yu Q, Yuan J, et al. Recurrent hypoglycemia increases hepatic gluconeogenesis without affecting glycogen metabolism or systemic lipolysis in rat. Metabolism: clinical and experimental. 2022;136:155310.
22.Roldán MB, Alonso M, Barrio R. Thyroid autoimmunity in children and adolescents with Type 1 diabetes mellitus. Diabetes, nutrition & metabolism. 1999;12(1):27-31.
23.Ghosh R, Chatterjee S, Dubey S, Pandit A, Ray BK, Benito-León J. Anti-Thyroid Peroxidase/Anti-Thyroglobulin Antibody-Related Neurologic Disorder Responsive to Steroids Presenting with Pure Acute Onset Chorea. Tremor and other hyperkinetic movements (New York, NY). 2020;10:19.
24.Cohen SB, Katsikis PD, Chu CQ, Thomssen H, Webb LM, Maini RN, et al. High level of interleukin-10 production by the activated T cell population within the rheumatoid synovial membrane. Arthritis Rheum. 1995;38(7):946-52.
25.Hansen D, Bennedbaek F, Hoier-Madsen M, Hegedus L, Jacobsen B. A prospective study of thyroid function, morphology and autoimmunity in young patients with type 1 diabetes. European journal of endocrinology. 2003;148(2):245-51.
26.Sharifi F, GHASEMI L, MOUSAVINASAB S. Thyroid function and anti-thyroid antibodies in Iranian patients with type 1 diabetes mellitus: influences of age and sex. 2008.
27.Balasa B, Davies JD, Lee J, Good A, Yeung BT, Sarvetnick N. IL-10 impacts autoimmune diabetes via a CD8+ T cell pathway circumventing the requirement for CD4+ T and B lymphocytes. Journal of immunology (Baltimore, Md : 1950). 1998;161(8):4420-7.
28.Pennline KJ, Roque-Gaffney E, Monahan M. Recombinant human IL-10 prevents the onset of diabetes in the nonobese diabetic mouse. Clinical immunology and immunopathology. 1994;71(2):169-75.
29.He JS, Xie PS, Luo DS, Sun CJ, Zhang YG, Liu FX. Role of immune dysfunction in pathogenesis of type 1 diabetes mellitus in children. Asian Pacific journal of tropical medicine. 2014;7(10):823-6.
30.Reis JS, Amaral CA, Volpe CM, Fernandes JS, Borges EA, Isoni CA, et al. Oxidative stress and interleukin-6 secretion during the progression of type 1 diabetes. Arquivos brasileiros de endocrinologia e metabologia. 2012;56(7):441-8.
31.Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. American journal of physiology Endocrinology and metabolism. 2001;280(5):E745-51.
32.Barton BE. The biological effects of interleukin 6. Medicinal research reviews. 1996;16(1):87-109.
33.Wędrychowicz A, Dziatkowiak H, Sztefko K, Wędrychowicz A. Interleukin-6 (IL-6) and IGF-IGFBP system in children and adolescents with type 1 diabetes mellitus. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association. 2004;112 8:435-9.
34.Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Journal of Clinical Epidemiology. 2009;62(10):1006-12.
35.Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40(11):1286-92.
36.Heier M, Margeirsdottir HD, Brunborg C, Hanssen KF, Dahl-Jørgensen K, Seljeflot I. Inflammation in childhood type 1 diabetes; influence of glycemic control. Atherosclerosis. 2015;238(1):33-7.
37.Talaat IM, Nasr A, Alsulaimani AA, Alghamdi H, Alswat KA, Almalki DM, et al. Association between type 1, type 2 cytokines, diabetic autoantibodies and 25-hydroxyvitamin D in children with type 1 diabetes. Journal of endocrinological investigation. 2016;39(12):1425-34.
38.Bradshaw EM, Raddassi K, Elyaman W, Orban T, Gottlieb PA, Kent SC, et al. Monocytes from patients with type 1 diabetes spontaneously secrete proinflammatory cytokines inducing Th17 cells. Journal of immunology (Baltimore, Md : 1950). 2009;183(7):4432-9.
39.Jacob CO, McDevitt HO. Tumour necrosis factor-alpha in murine autoimmune 'lupus' nephritis. Nature. 1988;331(6154):356-8.
40.Pan X, Kaminga AC, Kinra S, Wen SW, Liu H, Tan X, et al. Chemokines in Type 1 Diabetes Mellitus. Frontiers in immunology. 2021;12:690082.